Irinotecan therapy and molecular targets in colorectal cancer: A systemic review
Open Access
- 1 January 2009
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 15 (29), 3597-3602
- https://doi.org/10.3748/wjg.15.3597
Abstract
Irinotecan is the second line chemotherapy for advanced stage colorectal cancer (CRC) after failure of first line chemotherapy with oxaliplatin and 5-fluorouracil. The aim of this review is to analyse the data on irinotecan as second line chemotherapy for advanced CRC and the potential roles of the molecular markers, p53 and vascular endothelial growth factor (VEGF) in the management of advanced CRC. Thus, the English literature from 1980 to 2008 concerning irinotecan, p53, VEGF and CRC was reviewed. On review, Phase II and III clinical trials showed that irinotecan improves pain-free survival, quality of life, 1-year survival, progression-free survival and overall survival in advanced CRC. p53 and VEGF were expressed in CRC and had a predictive power of aggressive clinical behaviour in CRC. Irinotecan sensitizes p53 wild type, mutant and null cells to Fas-mediated cell apoptosis in CRC cells. Wild type p53 cells were more sensitive to irinotecan than mutated p53. Irinotecan has an anti-VEGF effect inhibiting endothelial cell proliferation, increasing apoptosis and reducing microvascular density which is only limited by irinotecan toxicity levels. To conclude, irinotecan improves the patient’s quality of life and the survival rates of patients with advanced CRC. p53 and VEGF status of the patients’ tumour is likely to affect the responsiveness of CRC to irinotecan. It is recommended that studies of the expression of these molecular markers in relation to chemo-responsiveness of irinotecan should be carried out for better management of patients with advanced CRC.This publication has 42 references indexed in Scilit:
- Targeting p53 for enhanced radio- and chemo-sensitivityApoptosis, 2009
- Mechanisms of lymphatic metastasis in human colorectal adenocarcinomaThe Journal of Pathology, 2009
- Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinibBritish Journal of Cancer, 2008
- Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literatureBritish Journal of Cancer, 2006
- Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal CancerClinical Cancer Research, 2006
- Increased Expression of Vascular Endothelial Growth Factor C in Papillary Thyroid Carcinoma Correlates with Cervical Lymph Node MetastasesClinical Cancer Research, 2005
- Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinomaCancer, 2000
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysisEuropean Journal Of Cancer, 1996